New State of the Art Drug Testing Products

Posted by TDDA

TDDA launches three new state-of-the-art workplace testing products.

At TDDA we’re always on the lookout for ways to make workplaces safer and more efficient. I’m delighted to tell you that we’ll be introducing three new technologies that do just that.

These new tests will detect a wider array of drugs more accurately. That means getting reliable, up to date testing results with less disruption in the workplace.

When we looked at TDDA testing data a few things stood out. We needed to deliver a best in class oral fluid testing product and address the issue of prescription opiates and synthetic cannabinoids.

With the recent release of the new oral fluid drug testing standard (AS/NZS 4760:2019), oral fluid testing is a hot topic both in Australia and New Zealand. To maintain our leadership in this space we’re introducing the ToxWipe™ 7.

TDDA has secured access to this new device that provides fast, accurate and effective oral screening. It detects up to 7 commonly abused drugs one of the most comprehensive on-site screening devices currently on the Australasian market.

These include:
• Amphetamine Type Substances
• Cannabinoids
• Cocaine and Metabolites
• Opiates
• Oxycodone
• Benzodiazepines*

*Not included in AS/NZS 4760:2019

Featuring the latest generation antibodies for improved performance and sensitivity, the ToxWipe™ 7 produces accurate results and only requires a small sample volume. This helps to reduce the impact of ‘dry mouth’, a common problem with oral fluid collection caused by a lack of available saliva.

The new ToxWipe™ 7 is compliant with the new AS/NZS 4760:2019 and available now!

In September, Australia and New Zealand will have exclusive access to the TDDA 7 Panel Urine Screen Cup. It’s is the first screening cup featuring a new Oxycodone strip.

Opiates and opioids remain a growing issue, you need only to look to America or Australia to see the problems prescription painkillers, legally obtained or otherwise, can cause for employers. The commonly prescribed Oxycodone did not produce a positive response in routine drug screens until now.

Compliant under Appendix B of the AS/NZS 4308:2008 Standard, TDDA’s new 7 Panel Urine Screen Cup will be a compliant and reliable way of detecting employees on Oxycodone in the workplace.

Due to the ever changing compounds in Synthetic Cannabinoids, we have to constantly scan the markets in order to detect the latest developments. TDDA now offers the most comprehensive testing utilising three different and unique drug types for detection in one easy to use device. TDDA’s new 3 Panel Synthetic Cannabis Dip Test is used in addition to urine testing and detects the synthetic cannabinoids JWH-018, JWH-073, AB-Pinaca, AB-Fubinaca and UR-144 5-Pentanoic Acid. It’s available from July, and is an extremely effective way to keep this ever emerging drug group from negatively impacting on your business.

TDDA is committed to delivering the best advice, policies, training and testing throughout Australasia. Our new tests are a demonstration to this commitment and we hope you reach out, ask some questions and let us show you our new products and services.

If you’re interested in a demonstration or want to learn more, please reach out to your TDDA representative or go to www.tdda.com to find your nearest office.

TDDA has ISO15189:2012 accreditation for workplace drug testing (see NATA and IANZ websites for further detail). TDDA is a drug and alcohol testing, education and training leader with more than 64 locations throughout Australasia. www.tdda.com

Share this post

Toxicology
Expertise

LAB BENCH

Current
Affairs

NEWS UPDATES

CEO
Updates

CEO CORNER